AAOS: Fondaparinux appears to be associated with elevated blood coagulation factors .
Thrombogenicity and Platelet Function in Lower Extremity Total Joint Arthroplasty: A Prospective Randomized Study
51 patients undergoing elective total knee and hip arthroplasty were randomized to receive thromboprophylaxis with either subcutaneous injection of fondaparinux (2.5 mg) or aspirin (325 mg) plus compression stockings. The purpose of this study was to determine whether changes in thrombogenicity can be measured with blood coagulation factors and platelet counts. Analysis of blood drawn on postoperative day 2 revealed significant increases in collagen-induced platelet aggregation and TIP-FCS in the fondaparinux group whereas no increases were observed with the aspirin group.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
